{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:03:45Z","timestamp":1769274225809,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T00:00:00Z","timestamp":1362441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s12185-013-1275-2","type":"journal-article","created":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T18:15:18Z","timestamp":1362420918000},"page":"456-464","source":"Crossref","is-referenced-by-count":38,"title":["Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice"],"prefix":"10.1007","volume":"97","author":[{"given":"Martin S.","family":"Tallman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George B.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie D.","family":"DeLeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Jay","family":"Graepel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Kollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,5]]},"reference":[{"key":"1275_CR1","first-page":"365","volume":"14","author":"E Vellenga","year":"1982","unstructured":"Vellenga E, Griffin JD. The biology of acute myeloid leukemia. Semin Oncol. 1982;14:365\u201371.","journal-title":"Semin Oncol"},{"issue":"4","key":"1275_CR2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","volume":"106","author":"MS Tallman","year":"2005","unstructured":"Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154\u201363.","journal-title":"Blood"},{"key":"1275_CR3","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanish","year":"2002","unstructured":"Rajvanish P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310\u20134.","journal-title":"Blood"},{"issue":"1","key":"1275_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","volume":"22","author":"LD DeLeve","year":"2002","unstructured":"DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27\u201342.","journal-title":"Semin Liver Dis"},{"key":"1275_CR5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/j.gastro.2009.05.009","volume":"137","author":"R Harb","year":"2009","unstructured":"Harb R, Xie G, Lutzko C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology. 2009;137:704\u201312.","journal-title":"Gastroenterology"},{"issue":"3","key":"1275_CR6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.22351","volume":"48","author":"LD DeLeve","year":"2008","unstructured":"DeLeve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48(3):920\u201330.","journal-title":"Hepatology"},{"key":"1275_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01695888","volume":"66","author":"E Carreras","year":"1993","unstructured":"Carreras E, Granena M, Navasa M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993;66:77\u201380.","journal-title":"Ann Hematol"},{"issue":"4","key":"1275_CR8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255\u201367.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"1275_CR9","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","volume":"2","author":"G McDonald","year":"2002","unstructured":"McDonald G. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin. Clin Lymphoma. 2002;2(Suppl 1):S35\u20139.","journal-title":"Clin Lymphoma"},{"key":"1275_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","volume":"30","author":"AM Cohen","year":"2002","unstructured":"Cohen AM, Luger SM, Sickles C, et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002;30:23\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1275_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001622-200003000-00001","volume":"12","author":"SI Bearman","year":"2000","unstructured":"Bearman SI. Veno-occlusive disease of the liver. Cur Opion Oncol. 2000;12:103\u20139.","journal-title":"Cur Opion Oncol"},{"key":"1275_CR12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/gut.2007.131136","volume":"57","author":"GB McDonald","year":"2008","unstructured":"McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut. 2008;57:987\u20131003.","journal-title":"Gut"},{"key":"1275_CR13","first-page":"3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Gut. 2001;19:3244\u201354.","journal-title":"Gut"},{"key":"1275_CR14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","volume":"16","author":"RA Larson","year":"2002","unstructured":"Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia.in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627\u201336.","journal-title":"Leukemia"},{"key":"1275_CR15","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442\u201351.","journal-title":"Cancer"},{"key":"1275_CR16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","volume":"92","author":"FJ Giles","year":"2001","unstructured":"Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic veno-occlusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406\u201313.","journal-title":"Cancer"},{"key":"1275_CR17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM, Angelotta C, Bennet CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31:599\u2013604.","journal-title":"Leuk Res"},{"key":"1275_CR18","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","volume":"26","author":"L Pagano","year":"2007","unstructured":"Pagano L, Fianchi L, Caira M, et al. The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26:3679\u201390.","journal-title":"Oncogene"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-013-1275-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1275-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:10Z","timestamp":1559452270000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-013-1275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,5]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1275-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,5]]}}}